These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 22562553)

  • 1. An SNP in CYP39A1 is associated with severe neutropenia induced by docetaxel.
    Uchiyama T; Kanno H; Ishitani K; Fujii H; Ohta H; Matsui H; Kamatani N; Saito K
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1617-24. PubMed ID: 22562553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Logistic regression analysis for febrile neutropenia (FN) induced by docetaxel in Japanese cancer patients.
    Ozawa K; Minami H; Sato H
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):551-7. PubMed ID: 18064462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer.
    Melchardt T; Hufnagl C; Magnes T; Weiss L; Hutarew G; Neureiter D; Schlattau A; Moser G; Gaggl A; Tränkenschuh W; Greil R; Egle A
    BMC Cancer; 2015 Oct; 15():725. PubMed ID: 26475344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics.
    Nieuweboer AJ; Smid M; de Graan AM; Elbouazzaoui S; de Bruijn P; Eskens FA; Hamberg P; Martens JW; Sparreboom A; de Wit R; van Schaik RH; Mathijssen RH
    Pharmacogenomics J; 2016 Nov; 16(6):519-524. PubMed ID: 26345519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia.
    Kiyotani K; Mushiroda T; Kubo M; Zembutsu H; Sugiyama Y; Nakamura Y
    Cancer Sci; 2008 May; 99(5):967-72. PubMed ID: 18294295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of protein-unbound docetaxel in cancer patients.
    Minami H; Kawada K; Sasaki Y; Igarashi T; Saeki T; Tahara M; Itoh K; Fujii H
    Cancer Sci; 2006 Mar; 97(3):235-41. PubMed ID: 16542221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of systemic exposure to unbound docetaxel and neutropenia.
    Baker SD; Li J; ten Tije AJ; Figg WD; Graveland W; Verweij J; Sparreboom A
    Clin Pharmacol Ther; 2005 Jan; 77(1):43-53. PubMed ID: 15637530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia.
    Hansson EK; Friberg LE
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):881-90. PubMed ID: 22057837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group.
    Pfisterer J; du Bois A; Wagner U; Quaas J; Blohmer JU; Wallwiener D; Hilpert F;
    Gynecol Oncol; 2004 Mar; 92(3):949-56. PubMed ID: 14984965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience with the management of neutropenia in gynecologic cancer patients receiving carboplatin-based chemotherapy.
    Markman J; Zanotti K; Webster K; Belinson J; Peterson G; Kulp B; Markman M
    Gynecol Oncol; 2004 Feb; 92(2):592-5. PubMed ID: 14766252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective analysis of severe neutropenia in patients receiving concomitant administration of docetaxel and clarithromycin.
    Tsuji D; Kamezato M; Daimon T; Taku K; Hatori M; Ikeda M; Hayashi H; Inoue K; Eto T; Itoh K
    Chemotherapy; 2013; 59(6):407-13. PubMed ID: 25011542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenomics variation in drug metabolizing enzymes and transporters in relation to docetaxel toxicity in Lebanese breast cancer patients: paving the way for OMICs in low and middle income countries.
    Awada Z; Haider S; Tfayli A; Bazarbachi A; El-Saghir NS; Salem Z; Shamseddine A; Taher A; Zgheib NK
    OMICS; 2013 Jul; 17(7):353-67. PubMed ID: 23758476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose individualisation in oncology using chemotherapy-induced neutropenia: Example of docetaxel in non-small cell lung cancer patients.
    Lombard A; Mistry H; Aarons L; Ogungbenro K
    Br J Clin Pharmacol; 2021 Apr; 87(4):2053-2063. PubMed ID: 33075149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.
    Hanna N; Shepherd FA; Fossella FV; Pereira JR; De Marinis F; von Pawel J; Gatzemeier U; Tsao TC; Pless M; Muller T; Lim HL; Desch C; Szondy K; Gervais R; Shaharyar ; Manegold C; Paul S; Paoletti P; Einhorn L; Bunn PA
    J Clin Oncol; 2004 May; 22(9):1589-97. PubMed ID: 15117980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance).
    Lewis LD; Miller AA; Owzar K; Bies RR; Markova S; Jiang C; Kroetz DL; Egorin MJ; McLeod HL; Ratain MJ;
    Pharmacogenet Genomics; 2013 Jan; 23(1):29-33. PubMed ID: 23188068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study.
    Alexandre J; Rey E; Girre V; Grabar S; Tran A; Montheil V; Rabillon F; Dieras V; Jullien V; Hérait P; Pons G; Treluyer JM; Goldwasser F
    Ann Oncol; 2007 Jan; 18(1):168-172. PubMed ID: 17060489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of pharmacokinetics and pharmacodynamics of docetaxel and Cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients?
    Minami H; Ohe Y; Niho S; Goto K; Ohmatsu H; Kubota K; Kakinuma R; Nishiwaki Y; Nokihara H; Sekine I; Saijo N; Hanada K; Ogata H
    J Clin Oncol; 2004 Jul; 22(14):2901-8. PubMed ID: 15254059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Open-label, randomized, single-dose, crossover study to evaluate the pharmacokinetics and safety differences between two docetaxel products, CKD-810 and Taxotere injection, in patients with advanced solid cancer.
    Cho EK; Park JY; Lee KH; Song HS; Min YJ; Kim YH; Kang JH
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):9-16. PubMed ID: 24337589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies.
    Whitworth JM; Matthews KS; Shipman KA; Numnum TM; Kendrick JE; Kilgore LC; Straughn JM
    Gynecol Oncol; 2009 Mar; 112(3):601-4. PubMed ID: 19110303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy-induced neutropenia does not correlate with DNA repair gene polymorphisms and treatment efficacy in advanced non-small-cell lung cancer patients.
    Iranzo V; Sirera R; Bremnes RM; Blasco A; Jantus-Lewintre E; Tarón M; Berrocal A; Blasco S; Caballero C; Del Pozo N; Rosell R; Camps C
    Clin Lung Cancer; 2011 Jul; 12(4):224-30. PubMed ID: 21726821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.